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88 The Journal of Thoracic and Cardiobjective: Optimal management of stage IIIA-N2 non–small cell lung cancer
emains controversial. The surgical arm of the North American Intergroup 0139 trial
as adopted as the standard treatment for patients with resectable N2 disease at the
niversity Health Network. Results after 7 years of experience are reported.
ethods: This is a retrospective study of consecutive patients with biopsy-proved
1-3 N2 M0 lung cancer who underwent induction chemoradiation before surgical
ntervention from January 1997 through August 2004. Induction chemotherapy
onsisted of cisplatin, 50 mg/m2, on days 1 and 8; etoposide, 50 mg/m2, on days 1
o 5, weeks 1 and 5; and concurrent daily external beam radiotherapy to 45 Gy. Lung
esection was performed within 6 weeks of completion of chemoradiation, followed
y 2 further cycles of consolidation chemotherapy.
esults: Between January 1997 and August 2004, 40 patients were treated according
o this protocol (25% T1, 62.5% T2, 7.5% T3, and 5% T4). Overall and disease-free
edian survivals were 40 and 37.1 months, respectively, whereas overall and
isease-free 3-year survivals were 51.7% and 52.3%, respectively. R0 resection was
chieved in 92.5%. The overall operative mortality rate was 7.5% (0% for lobec-
omy and 27% for pneumonectomy). Notably, all mortalities occurred within the
rst 2 years of our experience with this regimen.
onclusion: Chemoradiation before pulmonary resection in carefully selected pa-
ients with surgically resectable stage IIIA (N2) non–small cell lung cancer can lead
o improved overall and disease-free survival.
he burden of disease in stage IIIA (N2) non–small cell lung cancer (NSCLC)
varies from microscopic, single-station, mediastinal nodal involvement to
bulky, multistation, fixed, mediastinal nodal disease. Although the overall
rognosis for stage IIIA disease is poor, the prognosis varies based on the extent of
2 disease. Controversy regarding optimal management continues 12 years after
artini and colleagues’1 landmark article reporting the benefit of preoperative
hemotherapy for such patients. Subsequent randomized trials have reported con-
icting results.2-5 The results of the recently completed but as yet unpublished North
merican Intergroup 0139 randomized trial might clarify whether induction che-
oradiation followed by surgical resection has advantages over definitive
hemoradiation.
An interim analysis of the Intergroup 0139 trial6 demonstrated that induction
hemoradiation followed by surgical resection provided better progression-free
urvival but not overall survival. The excess mortality experienced by patients who
equired pneumonectomy after induction chemoradiotherapy adversely affected the
verall survival in the surgical group. The 26% operative mortality rate in patients
vascular Surgery ● July 2007
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G
TSndergoing pneumonectomy (29% mortality for complex
nd 21.7% for simple pneumonectomies) was unexpected
rom the phase II trials and is considered excessive in the
odern era. After closure of the 0139 trial, the surgical arm
f the protocol was adopted for all patients with resectable
tage IIIA-N2 disease at the Toronto General Hospital,
niversity Health Network.
aterials and Methods
his is a retrospective series of patients with biopsy-proved N2
isease who underwent surgical resection after induction chemo-
adiotherapy in our institution. During the time period of the study,
here were 550 patients treated at our cancer center with N2
isease. Of this group, 50 patients were treated with definitive
hemoradiotherapy (including 20 patients treated on the nonsurgi-
al arm of Intergroup 0139), and 40 patients were treated with
nduction chemoradiotherapy followed by surgical resection (in-
luding 16 patients treated on the surgical arm of Intergroup study
139). The remainder of the patients (460) did not receive or
omplete either of these treatment plans because of poor perfor-
ABLE 1. Patient characteristics and outcomes
haracteristics N (%)
Median survival
(mo) P value
OS DFS OS DFS
ll patients 40 40 37.1
ex .25 .28
Male 20 (50) 40 37.1
Female 20 (50) 27.3 26.3
T-detected N2 (1
cm)
.64 .53
Yes 29 (72.5) 41.7 37.1
No 11 (27.5) 22.3 20.9
nvolved nodes at
mediastinoscopy
.11 .36
Single 26 (65) NA† 37.1
Multiple 14 (35) 40 28.3
T status* .009 .12
1 10 (25) NA NA
2 25 (62.5) 40 26.3
3 3 (7.5) 9.6 NA
4 2 (5) NA 22.4
athologic Response* .006 .0006
None 13 (32.5) 21.1 18.4
CR  PR 27 (67.5) NA† 48.5
S, Overall survival; DFS, disease-free survival; CT, computed tomography;
A, not applicable; CR, complete pathological response; PR, partial patho-
ogic response. *Statistically significant difference. †Median survival not
Abbreviations and Acronyms
NSCLC non–small cell lung cancercet reached.
The Journal of Thoracicance status, medical comorbidities, or progression on treatment
r because they had already had part of their treatment (including
urgical intervention) before referral to our institution.
Involvement of N2 nodes was confirmed by means of medias-
inoscopy in all cases. Patients with T1 to T3 tumors were in-
luded, as well as those with T4 tumors if the T4 designation was
ue to satellite nodules but not other T4 categories. All patients
ere classified as having Eastern Cooperative Oncology Group
erformance status of 0 to 1 before induction treatment and pro-
eeded to surgical resection if there was no evidence of tumor
rogression on postinduction restaging with computed tomo-
raphic scans of the chest and abdomen, bone scans, and brain
agnetic resonance imaging.
Induction treatment consisted of 2 cycles of cisplatin, 50 mg/
2
, on days 1 and 8 and etoposide, 50 mg/m2, on days 1 to 5, with
oncurrent external beam radiation of 1.8 Gy per day beginning on
ay 1 to a total dose of 45 Gy in 25 doses. All patients completed
he induction regimen. Lobectomy or pneumonectomy with com-
lete mediastinal lymph node dissection was performed within 6
eeks of completion of the induction regimen. Two additional
ycles of consolidation chemotherapy were recommended postop-
ratively with the same drug combination.
A complex pneumonectomy was defined in this series as a
neumonectomy requiring intrapericardial dissection because of
ulky central disease. Disease-free survival (freedom from death
nd recurrence) and overall survival were calculated by applying
he Kaplan–Meier method starting at the date of the first chemo-
herapy treatment; the log-rank test was used to compare survival
urves. The statistical analysis was performed with version 9.1 of
he SAS System and User’s Guide (SAS Institute, Cary, NC).
esults
orty patients (20 male patients; mean age, 59.9  8.8
ears) completed the induction regimen between January
997 and August 2004. All patients who survived surgical
ntervention (37) received one cycle of postoperative che-
otherapy, and 35 received both cycles. Median follow-up
as 22 months. The majority of tumors were T2 (62.5%).
nlarged N2 nodes (1 cm) were detected by means of
ABLE 2. Morbidity and mortality by type of resection
Morbidity Mortality
ype of resection N N (%) N (%)
obectomy 29 2 (6.9) 0
neumonectomy 11 4 (36) 3 (27)
Right
Simple 2 0 0
Complex 4 3 (75) 2 (50)
Left
Simple 2 0 0
Complex 3 1 (33) 1 (33)
All simple 4 0 0
All complex 7 4 (57) 3 (43)
verall 40 6 (15) 3 (7.5)omputed tomography at a single station only in 65% of
and Cardiovascular Surgery ● Volume 134, Number 1 189
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G
TSatients (Table 1). Two patients with T4 satellite nodules
ere included in the analysis.
Overall and disease-free median survivals were 40 and
7.1 months, and overall and disease-free 3-year survivals
ere 51.7% and 52.3%, respectively (Figure 1). Overall
Figure 1. Overall survival.tFigure 2. Overall survival by T stage.
90 The Journal of Thoracic and Cardiovascular Surgery ● Julyurvival was better with lower T stages (P  .015, Figure
), and there was a trend toward improved disease-free
urvival. There was a trend toward better overall survival in
atients with single-station involvement, but this was not
tatistically significant (Figure 3). There was no significant
ifference in survival between patients with enlarged nodes
n computed tomographic scans versus those with normal-
ized nodes.
Pathologic response was categorized as no response ver-
us any response. Partial pathologic response or complete
athologic response was found in 20 (50%) and 7 (17.5%)
atients, respectively, for an overall response rate of 67.5%
27 patients), and this translated into a significant overall
Figure 4) and disease-free survival advantage. Resection
as accomplished in all patients by means of lobectomy in
9 and pneumonectomy in 11, with an overall operative
ortality rate of 7.5% and morbidity rate of 15% (Table 2).
here was no long-term survival difference between the 2
ypes of resections; however, operative mortality was 0%
or patients undergoing lobectomy, with a 6.9% morbidity
ate. There were few pneumonectomies, but these were
ssociated with a 27% operative mortality and a 36% mor-
idity. There was no mortality after 4 simple pneumonec-
igure 3. Overall survival by pathologic response. CR, Complete
athological response; PR, partial pathological response; MRD,
inimum residual disease defined as less than 10% viable tumor
ells; NR, no response.omies, but there were 3 deaths in 7 complex pneumonec-
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TSomies (43%), all of which occurred early (before 1999) in
ur experience. Right pneumonectomy was associated with
higher mortality (2/6 [33%]) versus left pneumonectomy
1/5 [20%]). Death was due to adult respiratory distress
yndrome in 2 patients and postoperative hemorrhage in 1
atient. Major morbidities included 2 instances of massive
ntraoperative hemorrhage from dissection of centrally lo-
ated tumors, one of which required cardiopulmonary by-
ass, and 1 each of cardiac tamponade and pulmonary
mbolism. Importantly, there was no mortality in the 34
onsecutive lung resections over the last 5 years of the
tudy, including 5 patients who required pneumonectomy.
0 resection was accomplished in 37 patients, with only 2
1 and 1 R2 resections. The site of relapse was distant in
9%, with the brain being the most common site of distant
etastasis in 62.5% of relapsing patients.
iscussion
he optimum treatment strategy for stage IIIA-N2 NSCLC
emains controversial. Although some patients are cured
ith surgical intervention alone, results vary depending on
he extent of nodal disease (29%–35%).7,8 Two small ran-
omized trials suggest that surgical intervention alone is
nferior to preoperative chemotherapy followed by surgical
esection for patients with clinically evident N2 disease,9,10
igure 4. Overall survival by number of involved nodal stations
etermined at mediastinoscopy.hereas a third trial showed no difference.11 In all 3 trials f
The Journal of Thoracicome patients received postoperative radiotherapy. Other
rials have suggested that adjuvant chemotherapy after sur-
ical resection might improve survival over surgical inter-
ention alone.12,13 On the basis of a number of phase II and
mall phase III trials, neoadjuvant chemotherapy followed
y surgical resection has been widely practiced. The North
merican Intergroup 0139 multi-institutional randomized
ontrolled trial addressed the question of definitive chemo-
adiation versus induction chemoradiation followed by sur-
ical resection for patients with stage IIIA-N2 NSCLC. The
ature results are awaited; however, the initial results of
his trial showed there was an increase in disease-free sur-
ival in the surgical arm, but there was no difference in
verall survival between the 2 treatment arms. The lack of
ifference in overall survival was attributed to early deaths
n the surgical arm attributable mostly to high operative
ortality after pneumonectomy (26%).6 On the basis of
hese preliminary results, many centers have avoided surgi-
al therapy in all patients with N2 disease and adopted
hemoradiotherapy alone as the standard treatment for stage
IIA-N2 NSCLC.
At the Toronto General Hospital, the surgical arm of the
ntergroup 0139 trial protocol was continued as the standard
reatment for selected fit patients with resectable stage
IIA-N2 NSCLC after closure of accrual to the trial. After
he initial presentation of the 0139 results, our impression
as that the improved disease-free interval in the surgical
rm might indeed be clinically important, and therefore we
eviewed our own center’s experience.
Our single-center experience with induction concurrent
hemoradiotherapy with cisplatin and etoposide with 45 Gy
f radiation demonstrates a median disease-free survival of
7 months and a median overall survival of 40 months. In
he surgical arm of the 0139 trial, median disease-free
urvival was 13.4 months, and median overall survival was
2 months. The 3-year disease-free survival and overall
-year survival in our series were 52% and 52%, respec-
ively, versus 37% and 28% in the surgical arm of the 0139
rial. We recognize that although a number of surgeons over
ime were involved, our results still represent a retrospective
tudy of a single-institution experience and therefore are not
irectly comparable with the results of a prospective mul-
icenter randomized trial. It is also important to note that our
esults are not based on an intention-to-treat analysis but
ather on a review of those selected patients who were able
o complete this treatment regimen and hence is inherently
iased. However, we believe that this is important informa-
ion in that it documents that there is a population of patients
ith N2 NSCLC who are candidates for potentially curative
urgical therapy. Moreover, careful analysis of such patients
rom a single institution might help to elucidate important
actors that ultimately might be applied to improve patient
and Cardiovascular Surgery ● Volume 134, Number 1 191
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G
TSelection outcomes of lung cancer treatment in this chal-
enging group of patients.
Similar to the 0139 trial, however, we found that there
as indeed significantly higher mortality in the subgroup of
atients who required a complex pneumonectomy to accom-
lish their resection, although only in this small subgroup.
urthermore, all deaths occurred early in our pre-1999 ex-
erience during accrual to the 0139 trial and none during the
ost-0139 experience. In the lobectomy (n 29) and simple
neumonectomy (n  4) subgroups, which comprised
7.5% of patients, mortality was 0%. Despite a 43% oper-
tive mortality rate for the total of 7 patients who underwent
omplex pneumonectomy, the median overall survival of
he entire group (including all patients undergoing resec-
ion) was 40 months, and 3-year survival was 51.7%, which
ompares favorably with the results of older published
eries.2,3,14,15
We attempted to identify the key factors that contributed
o the high mortality rate of complex pneumonectomy and
ound that all 3 mortalities occurred within the first 2 years
f our institution’s experience with neoadjuvant chemora-
iation. Of the 3 mortalities, all patients had bulky central
umors with challenging operations. The cause of death was
dult respiratory distress syndrome in 2 and hemorrhage in
he third. The subsequent 34 patients (including 2 additional
atients who underwent complex pneumonectomies) and 4
ho required only simple pneumonectomies did not expe-
ience a single mortality.
The hazards of performing a lung resection after induc-
ion chemotherapy with or without radiation have been
nvestigated, with variable results reported; however, the
arger series have consistently reported higher morbidity
nd mortality rates after induction compared with standard
ung resections. Overall reported mortality rates for lung
esections for primary lung cancer without induction are
.3% to 3.7%,16-18 with rates for lobectomy of 1.2% to 2.9%
nd 3.2% to 6.2% for pneumonectomy, whereas the larger
eries of postinduction lung resections report operative mor-
alities of 2.4% to 3.8% for lobectomy and 7.2% to 12% for
neumonectomy.18-20
Exploratory analysis of the Intergroup 0139 data report-
ng a subset analysis of patients demonstrated that there was
significant survival advantage for patients who underwent
obectomy compared with a matched group who underwent
efinitive chemoradiation (34 vs 22 months’ median sur-
ival). There was no difference in survival, however, when
he pneumonectomy group was compared with a matched
hemoradiation group.6 This trial had a 21.7% operative
ortality rate for simple pneumonectomy, as opposed to our
urrent experience of 0% mortality. The smoother postop-
rative courses of our current-era patients undergoing pneu-
onectomy leads us to believe that the operative mortalityate for this subgroup will continue to be acceptably low and w
92 The Journal of Thoracic and Cardiovascular Surgery ● Julyhat, similar to the lobectomy subgroup, they should be
electively considered for a strategy of neoadjuvant
hemoradiation.
In our review we found that, over time, surgeons selected
ewer patients with bulky central tumors or with bulky
ultistation disease, in which resection might have been
redicted to be difficult. However, there was no change in
he number of patients with single-station disease. From a
hysiologic perspective, we did not observe any changes
ver time in pulmonary function testing. Our results suggest
hat with increased experience and refined patient selection,
reatment according to the surgical arm of the 0139 trial is
afe and might lead to improved survival in patients with
IIA-N2 lung cancer compared with historical reports or the
ntergroup 0139 trial. On the basis of our results, we believe
hat carefully selected patients with stage IIIA-N2 NSCLC
hould be offered neoadjuvant chemoradiotherapy followed
y surgical resection. We believe that better patient selec-
ion, operative technique, and increased experience operat-
ng after chemoradiotherapy contributed to this improve-
ent in results.
In many centers, definitive chemoradiotherapy has be-
ome the recommended treatment in patients who require
neumonectomy because of the high operative mortality
eported in the Intergroup 0139 trial. The recently presented
uropean Organization for Research and Treatment of Can-
er 08941 trial reports equivalent survival for patients
reated with chemotherapy followed by either radiation or
urgical intervention.21 This trial, however, specifically in-
luded patients with stage IIIA disease “in whom the nodal
isease (N2) was considered irresectable” by the thoracic
urgeon at the time of initial assessment. We concur that
uch patients are likely best managed with definitive che-
oradiotherapy, whereas for those patients in whom the
odal disease and primary tumor are technically resectable,
urgical intervention should be considered as part of the
reatment algorithm.
onclusions
n the basis of our results, patients at our center with stage
IIA-N2 NSCLC whose tumors are amenable to a lobec-
omy or pneumonectomy are offered neoadjuvant chemora-
iation before surgical resection as the treatment of choice.
learly, this treatment strategy is not accepted universally,
nd the role of surgical intervention in stage III N2 NSCLC
ontinues to be debated. We believe that highly selected
atients in whom disease is considered technically resect-
ble (particularly those with microscopic N2 disease) do
ave a chance to achieve improved long-term survival with
rimodality therapy. As with any complex therapy, contin-
ed experience with careful analysis and reporting of results
ill allow us to more clearly define the patients who are
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Uy et al General Thoracic Surgeryost likely to derive benefit from multimodality treatment
or stage IIIA-N2 lung cancer.
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